uMETHOD partners with Getlabs to make personalized cognitive decline care plans available in Arizona - MedCity News

In another sign that healthcare is take-outTtwo healthcare startups entered into a partnership on Wednesday to help provide at-home diagnostics for patients with cognitive decline.

uMETHODwhich provides precision medicine software to treat cognitive decline that can lead to Alzheimer’s, home diagnostics provider tapped Getlabs to provide mobile phlebotomies for their patients in Arizona.

AAlzheimer’s disease is becoming more significant public health crisis in Arizona – more than 150,000 Arizonans age 65 and older are living with the disease and 15-20% of Arizonans age 60 and older have mild cognitive impairment.

Once patients are diagnosed with cognitive decline, Medicare requires their doctors to identify and address treatable and reversible causes of the condition. There are 60 or 70 of these potentially reversible causes of cognitive decline, so doctors must look at an extensive data set for each individual patient to identify what active causes they may haveuMETHOD CEO Vic Chandra said in an interview.

“We really need to understand where they are biologically, medically — and that requires a very broad look at their blood test results and medical status,” Chandra said. “And so the blood draw is an absolutely critical, essential part of identifying these reversible causes and then being able to address them.”

However, it is important to remember that most patients with cognitive decline are aged 65 and older. At that age, driving to a blood collection center or arranging transportation there often becomes more of a challenge — one that is further compounded by cognitive decline, according to Chandra.

Kyle Mickelson, founder and CEO of Getlabs, agreed. One of the biggest reasons patients with cognitive decline can’t stick to their care plans is missed lab orders, he said in an interview.

By adding Getlabs home phlebotomy services to theirs RestoreU care program, uMETHOD hopes to increase the number of patients with cognitive decline who have their blood drawn. The program is designed to minimize the patient’s risk of developing Alzheimer’s and slow the progression of the disease.

Under the program, the doctor orders a blood test from Sonora Quest Laboratories — Arizona’s largest diagnostic lab — and a Getlabs mobile phlebotomist administers this blood test at patient at home. uMETHOD then combines the patient’s medical history with the blood test results in its AI-based platform. The system creates a care plan that goes to the doctor, who will use it to decide how best to treat the patient and address their unique causes of cognitive decline.

These personalized care plans include recommendations for things like pharmacologic and supplement-based therapies, any additional diagnostics that may be needed, nutritional deficiencies that may need to be addressed, and medication management strategies to minimize risk. from brain fog and falling.

Ensuring that patients have convenient access to phlebotomies is essential because without these tests, uMETHOD would not have the clinical information needed to develop their personalized care plan, Chandra pointed out.

When doctors can get personalized care plans for patients early in their stages of cognitive decline, they can address treatable causes earlier and potentially keep patients from losing their independence or having to stay in expensive wards for memory care, Chandra said.

Photo: Anastasia Usenko, Getty Images

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *